{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:59:18Z","timestamp":1789502358144,"version":"build-2803163510"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009988","name":"Huzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009988","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This review summarizes key actionable molecular alterations in thyroid cancer and examines how molecular profiling can be translated into practical, subtype-specific targeted treatment strategies for advanced, recurrent, or radioiodine-refractory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative synthesis was performed using evidence from landmark clinical trials, current consensus guidelines, and representative translational studies on thyroid cancer drivers and targeted therapies. Molecular targets were categorized by signaling pathways and pathological subtypes (DTC, PTC\/FTC, ATC\/PDTC, and MTC), with emphasis on clinical indications, efficacy signals, and toxicity profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The identification of specific genomic drivers, such as BRAF V600E, RET mutations\/fusions, and NTRK fusions, has revolutionized the management of thyroid cancer. Precision highlights include the use of BRAF\/MEK inhibitors in BRAF-mutant ATC and highly selective RET or TRK inhibitors for fusion-positive tumors. For cases lacking these specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remains the standard of care for RAIR-DTC. Furthermore, \u201credifferentiation\u201d therapies show promise in restoring radioiodine sensitivity, while emerging pathways like PI3K\/AKT\/mTOR and immune checkpoints offer new avenues for combination therapy to overcome treatment resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The therapeutic paradigm in thyroid cancer is shifting from non-selective multikinase inhibition toward molecularly matched, combination-based, and adaptively sequenced strategies. Early and comprehensive genomic profiling\u2014including fusion detection\u2014is essential to optimize treatment selection, address resistance, and expand precision therapy options across disease subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1810813","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:50:15Z","timestamp":1780635015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted therapy in thyroid cancer: molecular alterations and clinical management"],"prefix":"10.3389","volume":"17","author":[{"given":"YiHeng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YeSheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Huzhou Hospital, Zhejiang University School of Medicine","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongCan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoXin","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoChao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.110","article-title":"The changing incidence of thyroid cancer","volume":"12","author":"Kitahara","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.127","article-title":"Thyroid cancer stem cells","volume":"7","author":"Lin","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.10.008","article-title":"Differentiated thyroid cancer","volume":"37","author":"Burns","year":"2010","journal-title":"Semin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1078-0432.CCR-22-0873","article-title":"FDA approval summary: cabozantinib for differentiated thyroid cancer","volume":"28","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114500","article-title":"Targeted therapy and drug resistance in thyroid cancer","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932353","article-title":"RET signaling pathway and RET inhibitors in human cancer","volume":"12","author":"Regua","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00598-y","article-title":"Pathogenesis of cancers derived from thyroid follicular cells","volume":"23","author":"Fagin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030710","article-title":"MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data","volume":"15","author":"Schubert","year":"2023","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCO.0000000000000797","article-title":"BRAF mutations in thyroid cancer","volume":"34","author":"Scheffel","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115744","article-title":"BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells","volume":"22","author":"Bonaldi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-020-05521-2","article-title":"BRAFV600E mutation is associated with an increased risk of papillary thyroid cancer recurrence","volume":"44","author":"Enumah","year":"2020","journal-title":"World J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03539-7","article-title":"BRAF V600E mutation in thyroid carcinoma: a large-scale study in han chinese population","volume":"22","author":"Cong","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab286","article-title":"BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer","volume":"106","author":"Tao","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.959089","article-title":"Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S308910","article-title":"The association between radioiodine refractory in papillary thyroid carcinoma, sodium\/iodide symporter expression, and BRAFV600E mutation","volume":"14","author":"Anekpuritanang","year":"2021","journal-title":"OncoTargets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/jca.33105","article-title":"The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer","volume":"11","author":"Ge","year":"2020","journal-title":"J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamaoncol.2024.2133","article-title":"Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST multidisciplinary group consensus statement","volume":"10","author":"Hamidi","year":"2024","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an international thyroid oncology group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK\u2013RAS\u2013RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18801","article-title":"Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer","volume":"13","author":"De Matos","year":"2025","journal-title":"PeerJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad697","article-title":"Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer","volume":"109","author":"Mu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-24-0146","article-title":"Management of follicular thyroid carcinoma","volume":"13","author":"Yamazaki","year":"2024","journal-title":"Eur Thyroid J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23719","DOI":"10.1038\/s41598-024-75087-9","article-title":"TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer","volume":"14","author":"Tan","year":"2024","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1346476","article-title":"Systemic treatments for radioiodine-refractory thyroid cancers","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1210\/clinem\/dgaf366","article-title":"Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues","volume":"111","author":"Hamidi","year":"","journal-title":"nd"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non\u2013small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET fusion-positive non-small cell lung cancer: the evolving treatment landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31681","article-title":"Efficacy and safety of selpercatinib in treating RET-altered MTC: a single-arm meta-analysis","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"key":"B40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised american thyroid association guidelines for the management of medullary thyroid carcinoma: the American thyroid association guidelines task force on medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid\u00ae"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2025.01.18","article-title":"Characteristics of RET gene mutations in Vietnamese medullary thyroid carcinoma patients: a single-center analysis","volume":"59","author":"Pham","year":"2025","journal-title":"J Pathol Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0117","article-title":"RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis","volume":"30","author":"Bulanova Pekova","year":"2023","journal-title":"Endocr-Relat Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET -mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses toward precision medicine in RET -altered solid tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103957","article-title":"NTRK fusions in thyroid cancer: pathology and clinical aspects","volume":"184","author":"Ma","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219589120","article-title":"Phase separation underlies signaling activation of oncogenic NTRK fusions","volume":"120","author":"Zhu","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amsu.2022.103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea","year":"2022","journal-title":"Ann Med Surg"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx209","article-title":"Investigation of the relationship between radiation dose and gene mutations and fusions in post-chernobyl thyroid cancer","volume":"110","author":"Efanov","year":"2018","journal-title":"Jnci: J Natl Cancer Inst"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2022.02.009","article-title":"NTRK-fusions in pediatric thyroid tumors: current state and future perspectives","author":"Casado-Medrano","year":"2022","journal-title":"Cancer Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0524","article-title":"Redifferentiating effect of larotrectinib in NTRK -rearranged advanced radioactive-iodine refractory thyroid cancer","volume":"32","author":"Groussin","year":"2022","journal-title":"Thyroid\u00ae"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00467","article-title":"Larotrectinib before initial radioactive iodine therapy in pediatric TRK fusion\u2013positive papillary thyroid carcinoma: time to reconsider the treatment paradigm for distantly metastatic disease","volume":"6","author":"Waguespack","year":"2022","journal-title":"Jco Precis Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70017","article-title":"Repotrectinib: redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer","volume":"14","author":"Desilets","year":"2024","journal-title":"Clin Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2777","article-title":"Repotrectinib exhibits potent antitumor activity in treatment-na\u00efve and solvent-front\u2013mutant ROS1-rearranged non\u2013small cell lung cancer","volume":"26","author":"Yun","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20090387","article-title":"Anaplastic lymphoma kinase: signalling in development and disease","volume":"420","author":"Palmer","year":"2009","journal-title":"Biochem J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908894","article-title":"Anaplastic lymphoma kinase-special immunity and immunotherapy","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02161-7","article-title":"Oncogenic gene fusions in cancer: from biology to therapy","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09808-1","article-title":"Clinicopathologic features and cytologic correlation of ALK-rearranged papillary thyroid carcinoma: a series of eight cases","volume":"35","author":"Shih","year":"2024","journal-title":"Endocr Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0325","article-title":"Characterization of thyroid cancer driven by known and novel ALK fusions","volume":"26","author":"Panebianco","year":"2019","journal-title":"Endocr-Relat Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0802","article-title":"RET , NTRK , ALK , BRAF , and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid\u00ae"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgad500","article-title":"Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer","author":"Ju","year":""},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0511","article-title":"Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors","volume":"22","author":"Hamatani","year":"2012","journal-title":"Thyroid"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.102","article-title":"Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the chernobyl accident","volume":"4","author":"Arndt","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.25.642535","article-title":"ALK inhibition prolongs survival in a mouse model of ALK-positive anaplastic thyroid cancer","volume":"36","author":"Machlah","year":"2025"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK -positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-655","article-title":"Will INSPIRE crown iruplinalkib as a new standard choice in first-line advanced ALK-positive non-small cell lung cancer","volume":"14","author":"Resuli","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126734","article-title":"Antineoplastic effect of ALK inhibitor crizotinib in primary human anaplastic thyroid cancer cells with STRN\u2013ALK fusion in vitro","volume":"25","author":"Ferrari","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5306\/wjco.v11.i7.495","article-title":"Complete response in anaplastic lymphoma kinase\u2013rearranged oncocytic thyroid cancer: a case report and review of literature","volume":"11","author":"Salins","year":"2020","journal-title":"World J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1261860","article-title":"Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review","volume":"14","author":"Buczy\u0144ska","year":"2023","journal-title":"Front Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112775","article-title":"Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer","volume":"13","author":"Melaccio","year":"2021","journal-title":"Cancers"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70313","article-title":"Angiogenesis and targeted therapy in the tumour microenvironment: from basic to clinical practice","volume":"15","author":"Yang","year":"2025","journal-title":"Clin Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.933648","article-title":"Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: systematic review and network meta-analysis","volume":"13","author":"Ji","year":"2022","journal-title":"Front Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0054","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","journal-title":"Thyroid"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.01.029","article-title":"A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study","author":"Ravaud","year":""},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET\u2013positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00384","article-title":"Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and sorafenib in Korea","volume":"10","author":"Kim","year":"2019","journal-title":"Front Endocrinol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","article-title":"1646MO phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032312","article-title":"Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect","volume":"24","author":"H\u00f8jer Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab102","article-title":"Thyroid hormone receptor beta inhibits PI3K-akt-mTOR signaling axis in anaplastic thyroid cancer via genomic mechanisms","volume":"5","author":"Davidson","year":"2021","journal-title":"J Endocr Soc"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03035-z","article-title":"Multi-node inhibition targeting mTORC1, mTORC2 and PI3K\u03b1 potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models","volume":"133","author":"Tyrakis","year":"2025","journal-title":"Br J Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/akt\/mTOR pathway and its role in cancer therapeutics: are we making headway","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0053","article-title":"Defining the in vivo role of mTORC1 in thyrocytes by studying the TSC2 conditional knockout mouse model","volume":"34","author":"Rossetti","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0874","article-title":"Oncogenic mutations in PI3K\/AKT\/mTOR pathway effectors associate with worse prognosis in BRAFV600E -driven papillary thyroid cancer patients","volume":"27","author":"Pappa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1176731","article-title":"Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance","volume":"14","author":"Hamidi","year":"2023","journal-title":"Front Endocrinol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.06.005","article-title":"Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma","volume":"164","author":"Milosevic","year":"2014","journal-title":"Transl Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043418","article-title":"Disulfiram\/cu kills and sensitizes BRAF-mutant thyroid cancer cells to BRAF kinase inhibitor by ROS-dependently relieving feedback activation of MAPK\/ERK and PI3K\/AKT pathways","volume":"24","author":"Xie","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116850","article-title":"Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for breast cancer therapy","volume":"236","author":"Garg","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1304188","article-title":"Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab\/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: A case report and literature review","volume":"15","author":"Oh","year":"2024","journal-title":"Front Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611643","article-title":"mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in Malignancies","volume":"30","author":"Sztankovics","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040830","article-title":"Combinatorial therapies in thyroid cancer: An overview of preclinical and clinical progresses","volume":"9","author":"Laetitia","year":"2020","journal-title":"Cells"},{"key":"B110","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3892\/ijo.2021.5234","article-title":"Everolimus therapy and side-effects: a systematic review and meta-analysis","volume":"59","author":"Arena","year":"2021","journal-title":"Int J Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","volume":"68","author":"Sadowski","year":"2016","journal-title":"Pharmacol Rep"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0414","article-title":"Translating the immune microenvironment of thyroid cancer into clinical practice","volume":"29","author":"Cunha","year":"2022","journal-title":"Endocr-Relat Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002284","article-title":"PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study","volume":"48","author":"Agarwal","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213632","article-title":"PD-L1 expression varies in thyroid cancer types and is associated with decreased progression free survival (PFS) in patients with anaplastic thyroid cancer","volume":"16","author":"Shobab","year":"2024","journal-title":"Cancers"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09552-y","article-title":"Regulation of PDL-1 expression in thyroid carcinoma cells by tumor cell derived cytokines activating STAT3","volume":"73","author":"Klemke","year":"2025","journal-title":"Immunol Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2024.0055","article-title":"Immune checkpoint inhibitors: Breakthroughs in cancer treatment","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005225","article-title":"Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3\/PD-L1 antibody, after checkpoint inhibitor progression: a case report","volume":"10","author":"Kroloff","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: From mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaf008","article-title":"CTLA-4\u2014two pathways to anti-tumour immunity","volume":"5","author":"Ward","year":"2024","journal-title":"Immunother Adv"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050777","article-title":"Modern therapeutic approaches in anaplastic thyroid cancer: a meta-analytic review of randomised and single arm studies on efficacy and survival","volume":"17","author":"Tunio","year":"2025","journal-title":"Cancers"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102849118","article-title":"Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response","volume":"118","author":"Gangaev","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2022.01.003","article-title":"Immunotherapy in anaplastic thyroid cancer: Case series","volume":"121","author":"Shih","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e18075","article-title":"Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC)","volume":"42","author":"Sehgal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid\u00ae"},{"key":"B135","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103042","article-title":"Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: a systematic review","volume":"141","author":"Tasong","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-23-0144","article-title":"Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers nontelomeric effects","volume":"21","author":"Landa","year":"2023","journal-title":"Mol Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0136","article-title":"TERT promoter mutations in thyroid cancer","volume":"70","author":"Matsuse","year":"2023","journal-title":"Endocr J"},{"key":"B140","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01244-8","article-title":"Regulation and clinical potential of telomerase reverse transcriptase (TERT\/hTERT) in breast cancer","volume":"21","author":"Yang","year":"2023","journal-title":"Cell Commun Signaling"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040735","article-title":"The C250T mutation of TERTp might grant a better prognosis to glioblastoma by exerting less biological effect on telomeres and chromosomes than the C228T mutation","volume":"16","author":"Gorria","year":"2024","journal-title":"Cancers"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104792","article-title":"Exploring the role of TERT in thyroid cancer: a systematic review","volume":"213","author":"Maloberti","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol Metab"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060939","article-title":"Prognostic significance of key molecular markers in thyroid cancer: a systematic literature review and meta-analysis","volume":"17","author":"Nguyen","year":"2025","journal-title":"Cancers"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2024.07.29","article-title":"TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer","volume":"58","author":"Pyo","year":"2024","journal-title":"J Pathol Transl Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112888","article-title":"TERT expression induces resistance to BRAF and MEK inhibitors in BRAF-mutated melanoma in vitro","volume":"15","author":"Delyon","year":"2023","journal-title":"Cancers"},{"key":"B149","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40164-025-00597-9","article-title":"Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics","volume":"14","author":"Shou","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B151","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J BioMed Sci"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311110","article-title":"An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma","volume":"24","author":"Rodriguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15465","article-title":"Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells","volume":"113","author":"Ohno","year":"2022","journal-title":"Cancer Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125867","article-title":"Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK\/ERK and PI3K\/AKT pathways","volume":"248","author":"Dang","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0690","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080008","article-title":"A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs","volume":"13","author":"Al-Abdallah","year":"2023","journal-title":"Front Oncol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41392-025-02129-7","article-title":"Molecular principles underlying aggressive cancers","volume":"10","author":"Nussinov","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B159","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.humpath.2007.05.012","article-title":"Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification","volume":"39","author":"Elliott","year":"2008","journal-title":"Hum Pathol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.041251","article-title":"Epidermal growth factor receptor status in anaplastic thyroid carcinoma","volume":"60","author":"Lee","year":"2007","journal-title":"J Clin Pathol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","article-title":"Targeted therapy for head and neck cancer: signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B162","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland Surg"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010179","article-title":"Targeted therapy for anaplastic thyroid carcinoma: advances and management","volume":"15","author":"Yuan","year":"2022","journal-title":"Cancers"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00165","article-title":"Phase II study of afatinib in patients with tumors with human epidermal growth factor receptor 2\u2013activating mutations: results from the national cancer institute\u2013molecular analysis for therapy choice ECOG-ACRIN trial (EAY131) subprotocol EAY131-B","author":"Bedard","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B166","first-page":"1","article-title":"HER2-targeted multimodal imaging of anaplastic thyroid cancer","author":"Wei","year":""},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02850-7","article-title":"IGF-1R targeting in cancer \u2013 does sub-cellular localization matter","volume":"42","author":"Soni","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020849","article-title":"Molecular targeting of the fibroblast growth factor receptor pathway across various cancers","volume":"25","author":"Shan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02842-y","article-title":"Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: A pilot study","volume":"76","author":"Yamazaki","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12851","article-title":"IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer","volume":"22","author":"Crezee","year":"2021","journal-title":"Oncol Lett"},{"key":"B171","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005621","article-title":"Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET\/CT: A case report","volume":"96","author":"Giannetta","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/ejh.2024.4048","article-title":"Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinoma","volume":"68","author":"Li","year":"2024","journal-title":"Eur J Histochem"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0216","article-title":"FGFR alterations in thyroid carcinoma: a novel class of primary drivers with significant therapeutic implications and secondary molecular events potentially mediating resistance in thyroid Malignancy","volume":"34","author":"Sabbagh","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"B175","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12141","article-title":"IGF bioregulation system in benign and Malignant thyroid nodular disease: a systematic review","volume":"34","author":"Karagiannis","year":"2020","journal-title":"In Vivo"},{"key":"B178","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.gendis.2022.03.002","article-title":"Drugging IGF-1R in cancer: new insights and emerging opportunities","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020555","article-title":"Disrupting insulin and IGF receptor function in cancer","volume":"22","author":"Cao","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.10.017","article-title":"Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer \u2013 real-world outcomes from UK centres","volume":"35","author":"Lorimer","year":"2023","journal-title":"Clin Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2024","journal-title":"Endocr-Relat Cancer"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signaling"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz244.068","article-title":"TPX-0046 is a novel and potent RET\/SRC inhibitor for RET-driven cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01259-x","article-title":"The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046","volume":"40","author":"Repetto","year":"2022","journal-title":"Invest New Drugs"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02006-9","article-title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01777","article-title":"Discovery of APS03118, a potent and selective next-generation RET inhibitor with a novel kinase hinge scaffold","volume":"68","author":"Zhong","year":"2025","journal-title":"J Med Chem"},{"key":"B190","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/816430","article-title":"A new aurora in anaplastic thyroid cancer therapy","volume":"2014","author":"Baldini","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13578-022-00934-z","article-title":"Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway","volume":"12","author":"Zhao","year":"2022","journal-title":"Cell Biosci"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05709-z","article-title":"Targeting aurora-a inhibits tumor progression and sensitizes thyroid carcinoma to sorafenib by decreasing PFKFB3-mediated glycolysis","volume":"14","author":"Jingtai","year":"2023","journal-title":"Cell Death Dis"},{"key":"B194","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The strange case of CDK4\/6 inhibitors: Mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Cancer"},{"key":"B195","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1247542","article-title":"CDK4 phosphorylation status and rational use for combining CDK4\/6 and BRAF\/MEK inhibition in advanced thyroid carcinomas","volume":"14","author":"Pita","year":"2023","journal-title":"Front Endocrinol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0011","article-title":"PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Endocr-Relat Cancer"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101403","article-title":"Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy","volume":"12","author":"Zou","year":"2025","journal-title":"Genes Dis"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21262","article-title":"Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E","volume":"8","author":"Antonello","year":"2017","journal-title":"Oncotarget"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122225","article-title":"Transcriptional targeting of oncogene addiction in medullary thyroid cancer","volume":"3","author":"Valenciaga","year":"2018","journal-title":"JCI Insight"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891580","article-title":"CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review","volume":"12","author":"Rampioni Vinciguerra","year":"2022","journal-title":"Front Oncol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s44178-024-00100-0","article-title":"The role of targeting CDK4\/6 in cancer immunotherapy","volume":"3","author":"Sun","year":"2024","journal-title":"Holist Integr Oncol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5564","article-title":"The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (review)","volume":"56","author":"He","year":"2025","journal-title":"Int J Mol Med"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0491","article-title":"Redifferentiation of radioiodine-refractory thyroid cancers","volume":"27","author":"Buffet","year":"2020","journal-title":"Endocr-Relat Cancer"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237021","article-title":"Redifferentiation therapies in thyroid oncology: molecular and clinical aspects","volume":"13","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2024","journal-title":"J Clin Med"},{"key":"B206","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/jcm7040061","article-title":"Epigenetic modifications in thyroid cancer cells restore NIS and radio-iodine uptake and promote cell death","volume":"7","author":"W\u00e4chter","year":"2018","journal-title":"J Clin Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050801","article-title":"Tumor-agnostic therapies in practice: challenges, innovations, and future perspectives","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers"},{"key":"B209","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00235","article-title":"Systemic treatment of thyroid cancer: ASCO guideline","author":"Saba","year":"2026","journal-title":"J Clin Oncol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0024","article-title":"Molecular predictive biomarker testing in advanced thyroid cancer \u2013 a european consensus","volume":"14","author":"Ry\u0161ka","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944","article-title":"2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer: american thyroid association anaplastic thyroid cancer guidelines task force","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid\u00ae"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0033","article-title":"NCCN guidelines\u00ae insights: thyroid carcinoma, version 1.2025: featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Haddad","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00321","article-title":"NTRK fusion\u2013positive thyroid carcinoma: from diagnosis to targeted therapy","author":"Marczyk","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0240","article-title":"MERAIODE: a phase II redifferentiation trial with trametinib and131 I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","author":"Leboulleux","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"B217","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1530\/EC-17-0302","article-title":"NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features","volume":"7","author":"Tavares","year":"2018","journal-title":"Endocrine Connections"},{"key":"B218","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1038\/s41467-025-58910-3","article-title":"Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers","volume":"16","author":"Pan","year":"2025","journal-title":"Nat Commun"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202503.1312.v1","article-title":"Mutational landmarks in anaplastic thyroid cancer: A perspective of a new treatment strategy","author":"Pakkianathan","year":"2025"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid cancer: updates and challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr Rev"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0164","article-title":"Next-generation sequencing on fine needle aspirates in neck recurrence of thyroid cancers","volume":"13","author":"Th\u00e9odon","year":"2024","journal-title":"Eur Thyroid J"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0104","article-title":"Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells","volume":"14","author":"Calafato","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B223","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CCO.0000000000001012","article-title":"Pathology and new insights in thyroid neoplasms in the 2022 WHO classification","volume":"36","author":"Lebrun","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET -activated thyroid cancer: Long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0006","article-title":"Advanced RAI-refractory thyroid cancer: an update on treatment perspectives","volume":"29","author":"Karapanou","year":"2022","journal-title":"Endocr-Relat Cancer"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF -mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid\u00ae"},{"key":"B227","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369780","article-title":"Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy","volume":"15","author":"Turner","year":"2024","journal-title":"Front Immunol"},{"key":"B229","article-title":"Medullary thyroid cancer","volume-title":"StatPearls","author":"Santillan","year":"2024"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer"},{"key":"B231","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-042320-034052","article-title":"Precision medicine in low- and middle-income countries","volume":"17","author":"Radich","year":"2022","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-024-01622-x","article-title":"Genomic testing in low- and middle-income countries (LMIC)","volume":"32","author":"Girisha","year":"2024","journal-title":"Eur J Hum Genet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1810813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:50:36Z","timestamp":1780635036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1810813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":232,"alternative-id":["10.3389\/fendo.2026.1810813"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1810813","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1810813"}}